- Home
- ARGX vs CBRE Comparison
ARGX vs CBRE Comparison
Compare ARGX & CBRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- CBRE
- Stock Information
- Founded
- ARGX 2008
- CBRE 1906
- Country
- ARGX Netherlands
- CBRE United States
- Employees
- ARGX N/A
- CBRE N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- CBRE Real Estate
- Sector
- ARGX Health Care
- CBRE Finance
- Exchange
- ARGX Nasdaq
- CBRE Nasdaq
- Market Cap
- ARGX 40.4B
- CBRE 36.2B
- IPO Year
- ARGX 2017
- CBRE 2004
- Fundamental
- Price
- ARGX $549.65
- CBRE $126.62
- Analyst Decision
- ARGX Strong Buy
- CBRE Buy
- Analyst Count
- ARGX 20
- CBRE 9
- Target Price
- ARGX $698.22
- CBRE $149.22
- AVG Volume (30 Days)
- ARGX 423.4K
- CBRE 1.8M
- Earning Date
- ARGX 05-08-2025
- CBRE 04-24-2025
- Dividend Yield
- ARGX N/A
- CBRE N/A
- EPS Growth
- ARGX N/A
- CBRE 2.39
- EPS
- ARGX 15.94
- CBRE 3.28
- Revenue
- ARGX $2,643,062,000.00
- CBRE $36,742,000,000.00
- Revenue This Year
- ARGX $60.97
- CBRE $13.34
- Revenue Next Year
- ARGX $31.50
- CBRE $9.46
- P/E Ratio
- ARGX $32.07
- CBRE $38.33
- Revenue Growth
- ARGX 82.13
- CBRE 13.15
- 52 Week Low
- ARGX $352.77
- CBRE $84.24
- 52 Week High
- ARGX $678.21
- CBRE $147.75
- Technical
- Relative Strength Index (RSI)
- ARGX 36.21
- CBRE 56.04
- Support Level
- ARGX $529.11
- CBRE $123.35
- Resistance Level
- ARGX $658.93
- CBRE $127.35
- Average True Range (ATR)
- ARGX 17.55
- CBRE 3.12
- MACD
- ARGX -6.04
- CBRE 1.03
- Stochastic Oscillator
- ARGX 15.82
- CBRE 93.26
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
About CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.